[Form 4] Roivant Sciences Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Roivant Sciences (ROIV) Form 4 reports that non-employee director Ilan Oren received 2,296 common shares on 17 Apr 2025 under the company’s Non-Employee Director Compensation Plan (transaction code A, price $0). The grant was fully vested on the award date.

To satisfy withholding taxes, the issuer effected a “net-settlement” disposal of 115 shares at $11.65 per share (code F). Following these routine transactions, Oren’s direct beneficial ownership increases to 104,681 common shares.

No derivative positions were reported, and the filing contains no information on revenues, earnings, guidance or corporate strategy. The activity is standard director compensation with no material impact on the company’s capital structure or control.

Insights

Securities Analyst

TL;DR: Routine director share grant; immaterial to ROIV valuation.

The Form 4 shows a small equity grant to director Ilan Oren and a tax-related share withholding. The net addition of roughly 2.2k shares increases insider ownership by less than 0.01% of ROIV’s ~800 m shares outstanding, posing no dilution concerns. No open-market buying or selling signal is present, so the filing offers little insight into insider sentiment. Given the absence of derivative activity or large disposals, I view the disclosure as housekeeping rather than a market-moving event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Epperly Melissa B,

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/17/2025		A		1,609(1)	A	$0(1)	42,985	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

	By: /s/ Jo Chen, as Attorney-in-Fact for Melissa B. Epperly	07/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ROIV shares did director Ilan Oren acquire on 17 Apr 2025?

He received 2,296 common shares as a fully vested equity award.

Did Ilan Oren sell any Roivant Sciences shares in this Form 4?

No open-market sale occurred; 115 shares were withheld by the company at $11.65 solely to cover taxes.

What is Ilan Oren’s total ROIV share ownership after the transactions?

His direct beneficial ownership stands at 104,681 common shares.

Were any derivative securities reported in this Form 4 filing?

No, the filing lists no derivative securities acquired or disposed of.

Does the filing include financial performance or guidance for Roivant Sciences?

No. The Form 4 only details insider share movements and contains no financial metrics or outlook.